Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of probable, laboratory-supported probable, or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria~* Disease duration ≤ 24 months~* Disease progression in the past 3 months~* Score ≥ 2 at the item swallowing of the ALS Functional Rating Scale Revised~* Score ≥ 2 at the item walking of the ALS Functional Rating Scale Revised~* Treatment with steady regimen of riluzole for a minimum of 1 month before study entry, and desiring its continuation~* Able to give informed consent~* Written informed consent~Exclusion Criteria:~* Motor neuron diseases other than ALS~* Severe head trauma in the past~* History of seizures~* History of ischemic stroke or hemorrhage~* Pacemaker~* Metal implants in the head/neck region~* Severe comorbidity~* Intake of illegal drugs~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Real tDCS (Type: EXPERIMENTAL): 10 days anodal bilateral motor cortex and cathodal spinal tDCS
- Sham tDCS (Type: PLACEBO_COMPARATOR): 10 days sham bilateral motor cortex and sham spinal tDCS

Based on this trial design, predict the completion outcome and termination type (if applicable).